Electronic Caps Report NSAID Rescue Medication Usage

Article

A phase 3 study presented at PAINWeek 2016 in Las Vegas, Nevada, showed the benefits of using an electronic tracking system.

pain management, osteoarthritis, PAINWeek 2016, rheumatology, pharmacy, SoluMatrix meloxicam, Vivlodex, rescue medication, acetaminophen, NSAIDs

Rescue medications are used for a variety of conditions including asthma, hypertension, and arthritis. However, researchers have to rely on pill count and patient reports to figure out how often the drugs are used. A phase 3 study presented at PAINWeek 2016 in Las Vegas, Nevada, showed the benefits of using an electronic tracking system.

A collaborative team of physicians from California, New York, and Pennsylvania worked on this analysis. The goal was to find how well the Medication Event Monitoring Systems (MEMS) in recording data from patients with either hip or knee osteoarthritis.

The 403 participants, who were at least 40 years of age, were chronic users of non-steroidal anti-inflammatory drugs (NSAIDs) and/or acetaminophen. For 12 weeks, patients were randomly assigned to receive low-dose SoluMatrix meloxicam (Vivlodex) 5 mg, 10 mg, or placebo once per day. The participants also had access to rescue medication, acetaminophen 500 mg every four to six hours as needed. The MEMS cap recorded the day and time each time that the bottle was opened.

  • MD Magazine is on Facebook, Twitter, Instagram, and LinkedIn!

During the study period, patients who were taking either meloxicam 5 mg or 10 mg ended up taking less rescue medication than those on the placebo. On average, the daily rescue medication dosage was 313.6 mg in the meloxicam 10 mg group, 326.2 mg in the meloxicam 5 mg group, and 464.1 mg in the placebo group. Rescue event days averaged at 23.5, 25.3, and 33.9, respectively.

“A dose-related trend was observed in the average number of rescue events per patient over 12 weeks by time of day,” the authors explained. Those numbers for 10 mg, 5 mg, and placebo, respectively, were: >24:00-6:00: 1.9, 2.1 and 3.9; >6:00-12:00: 7.6, 7.6 and 13.5; >12:00-18:00: 6.5, 7.2 and 12.0; and >18:00-24:00: 8.0, 10.1 and 15.3.

The team concluded that the MEMS caps were able to gather real-time data and important insight into rescue events for patients with osteoarthritis.

Also on MD Magazine >>> More News from PAINWeek 2016 in Las Vegas

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.